Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Tax Provisions (2021 - 2025)

Historic Tax Provisions for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $602000.0.

  • Apellis Pharmaceuticals' Tax Provisions rose 33.33% to $602000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 2704.32%. This contributed to the annual value of $1.2 million for FY2024, which is 4549.72% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Tax Provisions stood at $602000.0 for Q3 2025, which was up 33.33% from $500000.0 recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Tax Provisions ranged from a high of $1.4 million in Q4 2023 and a low of -$1.5 million during Q4 2022
  • For the 5-year period, Apellis Pharmaceuticals' Tax Provisions averaged around $362250.0, with its median value being $346500.0 (2021).
  • Its Tax Provisions has fluctuated over the past 5 years, first plummeted by 51789.77% in 2022, then skyrocketed by 33859.65% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Tax Provisions stood at $352000.0 in 2021, then plummeted by 517.9% to -$1.5 million in 2022, then skyrocketed by 196.74% to $1.4 million in 2023, then plummeted by 81.59% to $262000.0 in 2024, then soared by 129.77% to $602000.0 in 2025.
  • Its Tax Provisions stands at $602000.0 for Q3 2025, versus $500000.0 for Q2 2025 and $341000.0 for Q1 2025.